These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31283665)

  • 1. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk.
    Masset C; Boucquemont J; Garandeau C; Buron F; Morelon E; Girerd S; Ladrière M; Mourad G; Garrigue V; Cassuto E; Albano L; Foucher Y; Dantal J;
    Transplantation; 2020 Mar; 104(3):613-622. PubMed ID: 31283665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients.
    Masset C; Kerleau C; Blancho G; Hourmant M; Walencik A; Ville S; Kervella D; Cantarovich D; Houzet A; Giral M; Garandeau C; Dantal J;
    Transpl Int; 2023; 36():10816. PubMed ID: 36819125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function.
    Liu Y; Liu H; Shen Y; Chen Y; Cheng Y
    Transplant Proc; 2018 Oct; 50(8):2368-2370. PubMed ID: 30316359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
    Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
    Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Delayed Introduction of Tacrolimus in Kidney Transplants Using Type-III Donors After Circulatory Death.
    Ruiz-Martínez L; De-Cos-Gómez M; Valero-San-Cecilio R; Rodrigo-Calabia E; Heras-Vicario M; Serrano-Soto M; Belmar-Vega L; Palomar-Fontanet R; Miñambres-García E; Ruiz-San-Millán JC
    Transplant Proc; 2019 Mar; 51(2):337-340. PubMed ID: 30879536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry.
    Lee JY; Kim SH; Park YH; Park JB; Lee SH; Yang J; Kim MS; Kim DG
    Kidney Res Clin Pract; 2022 Sep; 41(5):623-634. PubMed ID: 35977904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab.
    Pham C; Kuten SA; Knight RJ; Nguyen DT; Graviss EA; Gaber AO
    Transpl Infect Dis; 2020 Jun; 22(3):e13257. PubMed ID: 32031729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
    Charpentier B; Rostaing L; Berthoux F; Lang P; Civati G; Touraine JL; Squifflet JP; Vialtel P; Abramowicz D; Mourad G; Wolf P; Cassuto E; Moulin B; Rifle G; Pruna A; Merville P; Mignon F; Legendre C; Le Pogamp P; Lebranchu Y; Toupance O; Hurault De Ligny B; Touchard G; Olmer M; Purgus R; Pouteil-Noble C; Glotz D; Bourbigot B; Leski M; Wauters JP; Kessler M
    Transplantation; 2003 Mar; 75(6):844-51. PubMed ID: 12660513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
    AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
    Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.